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Background: We investigated an outbreak of gluteal abscesses following intramuscular (IM)
injections given at a clinic in rural China to identify the causative agent, source, and method
of exposure.
Methods: Wedefined a case as an abscess that appeared at the site of an injection given since June
1, 2006. We compared case rates by injection route, medication, and diluents. We reviewed
injection practices, and cultured abscesses and environmental sites for mycobacteria.
Results: From October through December 2006, 5.8% (n = 35) of 604 persons who had received
injections at the clinic developed a case. All 35 cases occurred in 184 patients (attack rate = 19.0%)
who had received IM injections with various drugs that had been mixed with normal saline (NS);
risk ratio =1; p < 0.0001. No cases occurred in the absence of NS exposure. We identified
Mycobacterium abscessus from eight abscesses and from the clinic water supply, and observed
the inappropriate reuse of a 16-gauge needle left in the rubber septum of 100 ml multiple-
dose bottles of NS in the clinic. Fourteen percent (n = 527) of the 3887 registered residents
of this village had been treated with IM drugs over a three-month period, often for minor illnesses.
Conclusions: This outbreak of M. abscessus occurred from exposure to extrinsically contami-
nated NS through improper injection practices. Frequent treatment of minor illnesses with IM
DOI of original article: 10.1016/j.ijid.2008.11.025.
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injections of antibiotics was likely an important contributing factor to the size of this
outbreak.
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Injection safety is an enormous global health challenge both
in the developing world, where safe injection practices are
often lacking, and in developed countries, where new tech-
nologies and the transition of clinical practice to less regu-
lated outpatient settings is occurring.1—3 Mycobacterium
abscessus and related rapid-growing mycobacteria (RGM)
have caused iatrogenic post-injection abscesses as well
as a variety of skin and soft tissue infections in these set-
tings.4—7 Outbreaks of post-injection abscesses from RGM
usually result from contamination of injectable solutions
or injection equipment in the immediate healthcare setting.7
They are particularly problematic in that antibiotic treat-
ment is often delayed because RGM are often resistant to
multiple antibiotics and require special culture media.7 In
addition to the need for vigilance to interrupt transmission
from these extrinsic local sources, there is the concern of
intrinsic contamination of a commercially distributed pro-
duct,8 with epidemic potential. Therefore, all clusters or
outbreaks of these abscesses demand prompt investigation.
InDecember2006,wereceiveda request to investigatewhy
abscesses had developed at sites of drug injections given at a
rural clinic (clinic Y) serving village Y in Guangdong Province,
China. Acid-fast bacilli (AFB) were identified from four of five
abscesses. Initial interviews and a review of medical records
indicated that all the patients had received cefradine, ribos-
tamycin, dexamethasone, or ribavirin injections. Suspicion
was cast on these medications and on normal saline (NS).
We began an investigation to identify the causative agent,
source, and method of acquiring these abscesses.
Methods
Case finding
We defined a case as an abscess or persistent induration at
the site of any injection given between June 1, 2006, and
February 1, 2007, at any of the four village clinics affiliated
with one township hospital. We found cases by searching
medical records in all four village clinics, follow-up of
patients who had received intramuscular (IM) and/or intra-
venous (IV) injections at clinic Y, and a house-to-house search
of village Y. Physicians at the local township hospital had
performed incision and drainage of abscesses of patients at
the time of presentation for clinical care. They had sub-
mitted samples of pus to the clinical laboratory that served
their hospital. We obtained AFB isolates from the clinical
laboratory, determined their antibiotic sensitivities, and
identified them using standard biochemical techniques.
Retrospective cohort study
To identify which drug, diluent, or instrument was the source
of this outbreak, we identified all orders for IM or IV injec-
tions at clinic Y from August to October 2006. From these wedetermined the patient, medication, diluent, and route of
each injection. We then compared rates of abscess incidence
for each of these exposures.
Evaluation of injection practices and clinic
environment
We reviewed injection procedures in the treatment room.We
ascertained the manufacturer and lot numbers of all inject-
able drugs and the source of other components of each
injection. Using standard environmental sampling meth-
ods,9,10 we took environmental specimens of air, materials,
surfaces, and water (including well water supply) to culture
for mycobacteria.
We undertook this investigation to respond to an acute
problem of adverse events. The principal objective was to
identify the mode of exposure and source of infection to
terminate the outbreak and benefit the affected community.
Responses of this nature are not considered research and
accordingly do not require institutional review board
approval. Moreover, we performed no additional procedures,
tests, data collection, or data analysis above those needed to
resolve the immediate public health problem.
Results
Case finding and characteristics
We identified 35 cases, including 33 in residents of village Y
and two in residents of a neighboring village. All 35 had
received injections from clinic Y. The onset of first noticeable
symptoms was from October 14, 2006 through January 22,
2007. The antecedent injections had been given from August
to October 2006. Ten cases occurred in males and 25 in
females. The ages of patients ranged from 8 months to 96
years. All 35 had abscesses and 69% (n = 24) also had persis-
tent induration at the injection site. Excluding two patients
with upper respiratory symptoms, 21% (n = 7) of patients also
had fever from >37 8C to 38.5 8C. Twenty-six percent (n = 9)
had inguinal lymphadenopathy. One case patient had
abscesses in both buttocks and the rest had abscesses in
either the left (49%; n = 17) or right (49%; n = 17) buttock.
Some case patients reported pain or hyperalgesia at the
injection site. Chest films were clear for all case patients.
Twenty-eight cases were treated by incision and drainage and
one by needle aspiration. Two abscesses drained sponta-
neously. Four patients did not receive treatment. Pus from
eight of 26 abscesses yielded M. abscessus. All eight isolates
were resistant to isoniazid, rifampin, p-aminosalicylic acid,
levofloxacin, and capreomycin. They were sensitive to clar-
ithromycin, amikacin, and ethambutol.
Retrospective cohort study
During the period of the cohort analysis, August through
October 2006, 838 injections were given to 604 patients at
Table 1 Exposures of 35 abscess case patients among 604 patients exposed to 838 injections from clinic Y by drug and route of
injection; Guangdong Province, China, August—October 2006
Injection type and druga Exposed Unexposed % Exposed Attack rate (%) RR 95% CI
Case Total Case Total Exposed Unexposed
Injection route
Any IM 35 527 0 77 87 6.6 0 1 -
Any IV 5 153 30 451 25 3.3 6.7 0.49 0.19—1.2
Only IV 0 77 35 527 13 0 6.6 0 -
IM injections
Any with NS 35 184 0 420 30 19.0 0 1 -
Any without NS 16 422 19 182 70 3.8 10.4 0.36 0.19—0.69
Only without NS 0 343 35 261 57 0 13.4 0 -
IM with NS in syringe by drugb
Ribostamycin 16 67 19 117 36 23.8 16.2 1.5 0.81—2.7
Cefradine 24 129 11 55 70 18.6 20 0.93 0.49—1.8
Ribavirin 8 45 27 139 24 17.8 19.4 0.92 0.45—1.9
Dexamethasone 26 140 9 44 76 18.6 20.5 0.91 0.46—1.8
IM without NS in syringe by drug
Dexamethasone 0 82 35 522 14 0 6.7 0 -
Ribavirin 0 7 35 597 1.2 0 5.9 0 -
RR, risk ratio; CI, confidence interval; IM, intramuscular injection; IV, intravenous injection; NS, normal saline.
a Patients may have been exposed to more than one injection type and drug.
b N = 184 patients.
Figure 1 Intramuscular injections with normal saline by date,
with rate for all cases and count for cases with only one injection;
clinic Y, Guangdong Province, China, August—October 2006.
Mycobacterium abscessus post-injection abscesses 539clinic Y. Of these patients 5.8% (n = 35) developed a case.
All 35 cases occurred in 184 patients (attack rate = 19.0%)
who had received IM injections with one or more of four
different drugs (cefradine, ribostamycin, dexamethasone,
and ribavirin) dissolved in NS (Table 1). Two of these drugs,
dexamethasone and ribavirin, did not require reconstitu-
tion in NS but were sometimes mixed in the same syringe
with drugs needing reconstitution in NS (cefradine and
ribostamycin). When given in this combination, dexa-
methasone and ribavirin were associated with an increased
risk of abscesses. In contrast, when given without NS, they
had zero risk. Among the 184 patients given IM injections
with NS, none of the four individual medications was
associated with a greater risk of abscesses. Finally, the
risk of having an abscess increased as the number of NS-
containing injections increased ( p < 0.05; Chi-square for
trend = 6.1). No patient receiving an injection without NS
developed a case.
To better define the period of exposure we calculated a
case-injection/total injection rate in intervals of one-third
month. We also identified 18 case patients who had
received only one intramuscular injection. The case-injec-
tion/total injection rate rose sharply from a baseline dur-
ing the middle of August (Figure 1). All cases had had one
or more IM injections containing NS between August and
October 2006. Injections of case patients who had received
only one injection began to appear in mid-August. The
clinic began to use 100 ml bottles of NS in June when it ran
out of 2 ml vials of NS. Injections with NS were stopped on
October 23, 2006. Using the nine cases with single injec-
tions who could report an onset day, we estimated the
median incubation period to be 31 days (range 13—87
days).Assessment of injection practices and clinic
environment
Beginning in June 2006, the nurse responsible for giving
injections at the clinic began using multiple-dose bottles
(100 ml) of NS (Figure 2) to dilute cefradine and ribostamy-
cin. The nurse routinely left a 16-gauge needle inserted
through the septum of the bottle. When the bottle was
not in use the nurse attached a syringe to the hub of this
needle. To prepare an injection the nurse would detach the
syringe from this needle, lay the syringe on the table and
attach another syringe to be used for injection to the needle
and withdrew NS. She would use this second syringe and NS to
dilute the drug. She would then aspirate drugs into the
second syringe, give the injection, and reattach the first
syringe to the needle in the saline bottle. The nurse stated
Figure 2 Normal saline bottle showing the open 16-gauge
needle and syringe used to plug the needle hub.
540 J. Yuan et al.that she changed the syringe used to plug the needle hub in
the NS bottle whenever she began using a new bottle of NS,
about every three to seven days. She never used disinfectant
to clean the septum of the NS bottle. To prepare the skin for
injection the nurse took cotton balls directly from original
bags and wet themwith 75% ethanol. The clinic stopped using
100 ml NS for IM injections on October 23, 2006 and stopped
cefradine or ribostamycin injections on November 13, 2006.
The nurse used the same lot of NS from June through October.
Environmental samples taken in December revealed M.
abscessus from the clinic well water. The well water was not
chlorinated or otherwise treated or disinfected. We found
AFB from the top of the cabinet for storing syringes, and the
sewage from the clinic, but these were not M. abscessus.
Sampling of 37 other sites including the injection table, the
cloth used to wipe down the table, the sink and drain, the
antiseptic solution, air, syringes, and needles did not yield
AFB. The nurse’s hands were negative for AFB and she had no
pulmonary disease.
Two of the three other clinics served by the township
hospital used NS from the same lot number and from the same
manufacturer. From August to December 2006 these two
clinics attended to 2649 outpatients and used 240 bottles
of the same lot of NS to prepare injections. The nurses in
these two clinics used the same technique for preparing drugs
for injection as the nurse at clinic Ywith one difference. They
opened a new bottle of NS each day. We identified no post-
injection abscesses among patients of those two clinics.
Village Y had a population of 3887 registered residents.
Using this population, we can estimate from our cohort datathat 14% (n = 527) received IM and 4% (n = 153) received IV
drugs over the three months covered by our investigation.
The clinic physician reported that he used parenteral drugs to
treat minor illnesses as he referred patients withmore severe
illnesses directly to the township hospital.
Discussion
We concluded that this outbreak of M. abscessus abscesses
occurred due to an unsafe injection practice, specifically the
reuse of syringes on 100 ml multiple-dose bottles of NS.
Outbreaks of post-injection abscesses from RGM, including
M. abscessus, have resulted from both intrinsic and extrinsic
contamination of injectable drug preparations or injection
equipment.8,11—14 In this investigation concerns about the
quality of the injectable drugs and the NS required that we
quickly distinguish between intrinsic and extrinsic contam-
ination. Several lines of evidence led us to the conclusion
that extrinsic contamination from the clinic was responsible.
These include the specific association with NS, exposure
dates beginning after one month of using the NS, the lack
of abscesses in other clinics that used the same NS, the lack of
association with any specific drug used with NS, the risk ratio
of zero for ribavirin and dexamethasone when they were not
combined with NS, and management of the multiple-dose NS
bottle that would allow contamination and time for growth of
M. abscessus in the NS. Finding M. abscessus in the clinic
water supply also supports this conclusion. In other health-
care related outbreaks of M. abscessus and other RGM, the
organism has also been found in the tap water supply.15,16 M.
abscessus is an aquatic organism that can propagate in water
or soil and can even grow in distilled water.17 Thus, finding it
in the clinic well is not highly specific, since it could be found
in any hospital or clinic water supply.18 Moreover, we could
not confirm thatM. abscessuswas present in the water at the
time of the exposure or determine how it was transferred
from the tap water to the NS.
The pattern of exposure days indicates that several bot-
tles of NS were used without incident from June through early
August, followed by more than nine consecutive contami-
nated NS bottles. This pattern would be unlikely if the
contamination had occurred sporadically from contamination
of the hub of the needle from airborne M. abscessus or if the
nipple of the syringe had picked up M. abscessus from the
tabletop or air. More likely, in early August one NS bottle was
contaminated via the open needle. Since M. abscessus can
multiply in water,17 this initial contamination would have led
to a more heavily contaminated bottle. Subsequent bottles
were probably contaminated if the nurse used the syringe
from a contaminated bottle to plug the needle of a new
bottle. Although the nurse denied doing this, we could not
postulate another mechanism for the serial contamination. In
the 11 previously reported outbreaks of post-injection RGM
abscesses, the source of the organism has been identified in
three.8,13,14 In two of these three the source was water and in
one it was soiling of the top of penicillin vials from a damp
storage area.
Underlying this outbreak, one can detect an important
contributing factor, the frequent use of injections of antibac-
terial and antiviral agents. Indeed, a recent outbreak of
abscesses from a related RGM (Mycobacterium massiliense)
followed injection with ribostamycin for minor respiratory
Mycobacterium abscessus post-injection abscesses 541infections.11 Patients in our outbreak often received only a
single injection of drugs that actually required multiple doses
over several days to be effective in treating any infection.
Although we did not explore the reasons for giving so many
ineffective injections, this observation is not unusual. Other
studies in poor, rural areas of China have revealed that 37—45%
of patients who consulted rural, township hospitals received
injections as treatment.19,20 These injection rates in these
studies and our investigation greatly exceed the 3.7% average
estimated for transitional and developing countries.21
Alternative outpatient treatments have contributed to a
larger number of incidents of post-injection abscesses from
RGM. Mesotherapy, which consists of soft tissue injection of a
variety of substances with local anesthetics, is popular in
France and Latin America. It has caused outbreaks and indi-
vidual cases.12,22—24 Tissue augmentation, consisting of injec-
tions of presumably inert substances by illicit practitioners,
has caused breast and facial abscesses.25,26 Outbreaks of post-
injection abscesses have also resulted from a jet injector used
in a podiatry clinic and an unregistered commercially distrib-
uted product containing hydrocortisone.8,13
The practice of leaving needles in multiple-dose vials was
modeled to all of the nurses in the four village clinics by the
chief nurse in the township hospital. Chinese hospital infection
management guidelines cover reuse of syringes and needles
and prohibit the reuse of a multiple-dose bottle for more than
24 hours for dilution of drugs.27 World Health Organization
guidelines on safe injections state categorically that the prac-
tice of leaving a needle or syringe and needle inserted con-
tinuously through the injection septum of a bottle is dangerous
and should not be done.21 In addition to halting this practice
locally, we also trained and required staff to follow correct
injection techniques using official guidelines and to assure a
safe water supply to the health services. Indeed, local efforts
to improve injection practices can be effective.28 Efforts to
reduce the frequency of inappropriate use of injections may
also be effective in preventing post-injection infections in
China and elsewhere.28,29 Such efforts would not only be
expected to reduce infections, but save costs as well.30
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